Literature DB >> 25342314

Management of elderly patients with gliomas.

Jaime Gállego Pérez-Larraya1, Jean-Yves Delattre2.   

Abstract

The current progressive aging of the population is resulting in a continuous increase in the incidence of gliomas in elderly people, especially the most frequent subtype, glioblastoma (GBM). This sociohealth shift, known as the "silver tsunami," has prompted the neuro-oncology community to investigate the role of specific antitumor treatments, such as surgery, radiotherapy, chemotherapy, and other targeted therapies, for these traditionally undertreated patients. Advanced age, a widely recognized poor prognostic factor in both low-grade glioma (LGG) and high-grade glioma patients, should no longer be the sole reason for excluding such older patients from receiving etiologic treatments. Far from it, results from recent prospective trials conducted on elderly patients with GBM demonstrate that active management of these patients can have a positive impact on survival without impairing either cognition or quality of life. Although prospective studies specifically addressing the management of grade 2 and 3 gliomas are lacking and thus needed, the aforementioned tendency toward acknowledging a therapeutic benefit for GBM patients might also apply to the treatment of patients with LGG and anaplastic gliomas. In order to optimize such etiologic treatment in conjunction with symptomatic management, neuro-oncology multidisciplinary boards must individually consider important features such as resectability of the tumor, functional and cognitive status, associated comorbidities, and social support. ©AlphaMed Press.

Entities:  

Keywords:  Elderly; Glioblastoma; Glioma; High-grade glioma; Low-grade glioma; Old patients

Mesh:

Year:  2014        PMID: 25342314      PMCID: PMC4257742          DOI: 10.1634/theoncologist.2014-0170

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  95 in total

Review 1.  Aging of the immune system as a prognostic factor for human longevity.

Authors:  Anis Larbi; Claudio Franceschi; Dawn Mazzatti; Rafael Solana; Anders Wikby; Graham Pawelec
Journal:  Physiology (Bethesda)       Date:  2008-04

2.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Authors:  Jaime Gállego Pérez-Larraya; François Ducray; Olivier Chinot; Isabelle Catry-Thomas; Luc Taillandier; Jean-Sébastien Guillamo; Chantal Campello; Annick Monjour; Stéphanie Cartalat-Carel; Maryline Barrie; Aymeri Huchet; Patrick Beauchesne; Mona Matta; Karima Mokhtari; Marie-Laure Tanguy; Jérôme Honnorat; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

3.  Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.

Authors:  François Ducray; Monica Sierra del Rio; Catherine Carpentier; Dimitri Psimaras; Ahmed Idbaih; Caroline Dehais; Gentian Kaloshi; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antonio Omuro; Marc Sanson; Jean-Yves Delattre; Khê Hoang-Xuan
Journal:  J Neurooncol       Date:  2010-06-17       Impact factor: 4.130

4.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.

Authors:  Michael Glantz; Marc Chamberlain; Qin Liu; N Scott Litofsky; Lawrence D Recht
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

5.  Short course of radiation therapy in elderly patients with glioblastoma multiforme.

Authors:  A Idbaih; S Taillibert; J-M Simon; D Psimaras; H-M Schneble; S Lopez; P Lang; T Toubiana; L Feuvret; J-Y Delattre; J-J Mazeron
Journal:  Cancer Radiother       Date:  2008-11-28       Impact factor: 1.018

6.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

7.  Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.

Authors:  Stephanie E Combs; Johanna Wagner; Marc Bischof; Thomas Welzel; Florian Wagner; Jürgen Debus; Daniela Schulz-Ertner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-29       Impact factor: 7.038

8.  Age as a predictive factor in glioblastomas: population-based study.

Authors:  Daisuke Kita; Ilja F Ciernik; Salvatore Vaccarella; Silvia Franceschi; Paul Kleihues; Urs M Lütolf; Hiroko Ohgaki
Journal:  Neuroepidemiology       Date:  2009-03-27       Impact factor: 3.282

9.  Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.

Authors:  Jill S Barnholtz-Sloan; Vonetta L Williams; John L Maldonado; Dilip Shahani; Heather G Stockwell; Marc Chamberlain; Andrew E Sloan
Journal:  J Neurosurg       Date:  2008-04       Impact factor: 5.115

10.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

Authors:  G Minniti; V De Sanctis; R Muni; F Filippone; A Bozzao; M Valeriani; M F Osti; U De Paula; G Lanzetta; V Tombolini; R Maurizi Enrici
Journal:  J Neurooncol       Date:  2008-02-05       Impact factor: 4.130

View more
  16 in total

1.  Is mortality due to primary malignant brain and other central nervous system tumors decreasing?

Authors:  Haley Gittleman; Courtney Kromer; Quinn T Ostrom; Rachel Blanda; Jeffrey Russell; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2017-05-03       Impact factor: 4.130

Review 2.  Survival in glioblastoma: a review on the impact of treatment modalities.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2016-03-10       Impact factor: 3.405

Review 3.  Current trends in the surgical management and treatment of adult glioblastoma.

Authors:  Richard M Young; Aria Jamshidi; Gregory Davis; Jonathan H Sherman
Journal:  Ann Transl Med       Date:  2015-06

4.  Machine Learning Models for Classifying High- and Low-Grade Gliomas: A Systematic Review and Quality of Reporting Analysis.

Authors:  Ryan C Bahar; Sara Merkaj; Gabriel I Cassinelli Petersen; Niklas Tillmanns; Harry Subramanian; Waverly Rose Brim; Tal Zeevi; Lawrence Staib; Eve Kazarian; MingDe Lin; Khaled Bousabarah; Anita J Huttner; Andrej Pala; Seyedmehdi Payabvash; Jana Ivanidze; Jin Cui; Ajay Malhotra; Mariam S Aboian
Journal:  Front Oncol       Date:  2022-04-22       Impact factor: 5.738

5.  A Comprehensive Analysis of Influence ERCC Polymorphisms Confer on the Development of Brain Tumors.

Authors:  Peiliang Geng; Juanjuan Ou; Jianjun Li; Yunmei Liao; Ning Wang; Ganfeng Xie; Rina Sa; Chen Liu; Lisha Xiang; Houjie Liang
Journal:  Mol Neurobiol       Date:  2015-08-13       Impact factor: 5.590

6.  Hyperthermotherapy enhances antitumor effect of 5-aminolevulinic acid-mediated sonodynamic therapy with activation of caspase-dependent apoptotic pathway in human glioma.

Authors:  Donghui Ju; Fumio Yamaguchi; Guangzhi Zhan; Tadashi Higuchi; Takayuki Asakura; Akio Morita; Hideo Orimo; Shaoshan Hu
Journal:  Tumour Biol       Date:  2016-02-04

Review 7.  Management of glioblastoma in elderly patients.

Authors:  Jacob S Young; Steven J Chmura; Derek A Wainwright; Bakhtiar Yamini; Katherine B Peters; Rimas V Lukas
Journal:  J Neurol Sci       Date:  2017-08-01       Impact factor: 3.181

8.  A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.

Authors:  Nijiati Kudulaiti; Zhirui Zhou; Chen Luo; Jie Zhang; Fengping Zhu; Jinsong Wu
Journal:  BMC Surg       Date:  2021-05-06       Impact factor: 2.102

Review 9.  Recent advances in cancer surgery in older patients.

Authors:  Siri Rostoft; Riccardo A Audisio
Journal:  F1000Res       Date:  2017-07-27

10.  Inhibition of tribbles protein-1 attenuates radioresistance in human glioma cells.

Authors:  Bo Tang; Wei Wu; Qing Zhang; Yongjin Sun; Yifen Cui; Fei Wu; Xiaowei Wei; Guangying Qi; Xingsi Liang; Fang Tang; Yunqian Li; Wenhai Fan
Journal:  Sci Rep       Date:  2015-11-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.